Medias Health Inc.

19/03/2018

Medias Health has being establishing itself in a role of Mergers and Acquisitions Advisory and Consultancy in the biopharma and biotech markets. New and exciting developments are on the way. Stay tuned!

07/12/2017

Global breast cancer study reveals 72 new mutations

21/09/2017

Our press release is out!

TORONTO, Sept. 21, 2017 /CNW/ - Medias Health Inc. is pleased to announce that it is presenting an esteemed surgical...

20/09/2017

We are continuing our work on creating awareness around new and alternative methods of fighting cancer. Please share this latest video from our Project. Thank you!

A short video in support of Medias Health campaign and efforts.

13/09/2017

Breaking: Medias Health Inc. is pleased to announce its support for and participation in the After Brest Cancer (ABC) Foundation annual Pink Diamond Gala 2017. This event will take place on September 24, 2017. As a partner of ABC, Medias Health invited Prof. Dr. med. Karl. R. Aigner, a leading specialist in Regional Chemotherapy (RCT) cancer treatment, as a keynote speaker for the event. As well, we will be introducing Tyme Inc. and their unique and very promising oncological product SM-88 (in medical trial in the USA and first time in Canada). Please note that after the Gala, there will be a Q&A session and presentation by Prof. Aigner about his work with RCT and by Tyme Inc. about their progress with SM-88. Information about purchasing tickets is at the link below:

Just another WordPress site

13/09/2017

You will find a lot of information about regional chemotherapy cancer treatment, including articles, interviews and testimonials from current patients. Visit https://regionalchemotherapy.com

11/09/2017

Breaking: On September 24, 2017, Medias Health inc. is partnering with After Brest Cancer Foundation in support of its annual Pink Diamond Gala 2017. We are pleased to bring Prof. Dr. med. Karl. R. Aigner, a leading specialist in Regional Chemotherapy cancer treatment, as a keynote speaker for the event. As well, we will be introducing Tyme Inc. and their unique and very promising oncological product SM-88 (in medical trial in the USA). After the gala, there will be a Q&A session and presentation by Prof. Aigner and Tyme Inc. Information about purchasing tickets is at the link below:

Just another WordPress site

29/08/2017

Making experimental cancer treatment decision with limited amount of information when a stage-4 cancer patient is running out of time is hard. Treatment options for cancer, including standard and experimental cancer treatments, are not limited to one or two isolated therapies.

Making experimental cancer treatment decision with limited amount of information when a stage-4 cancer patient is running out of time is hard.

16/08/2017

A distinct advantage of regional chemotherapy in all of its variants is that it increases the concentration of the drugs in the cancer-affected area. Often higher concentration of the drug equates to higher efficacy, improving cancer therapy benefits. Furthermore, regional chemotherapy aims to reduce the exposure of additional tissues to the chemotherapy agents, thus, minimizing the risk of severe adverse effects.

One advantage of regional chemotherapy is that it increases the concentration of the drugs in the cancer-affected area, improving cancer therapy benefits.

15/08/2017

It is hard to think about the experimental cancer treatment cost for anyone who is fighting a terrible disease like cancer. However, affordability of cancer treatments, and particularly alternative cancer treatments is an important subject.

It is hard to think about the experimental cancer treatment cost for anyone who is fighting a terrible disease like cancer.

10/08/2017

RCT is not a new treatment protocol. However, in some applications it is an experimental treatment, and very few medical teams can perform such therapies.
https://regionalchemotherapy.com/standard-cancer-treatment-fails-whats-next/

When standard cancer treatment fails, many patients and their families start anew, searching for alternatives, including experimental treatments.

25/07/2017

Selecting a new treatment option and finding the means to pay for it, are some of the decisions by those who are fighting. Whatever the decisions are, more often than not, they demand hard choices. Furthermore, these choices often have to be made fast, sometimes very fast, while looking into the eyes of ultimate uncertainty.
https://regionalchemotherapy.com/making-hard-decisions-fighting-cancer/

Experimental cancer treatments affordability is a big issue. It is inevitable that individuals with cancer will be making hard decisions fighting cancer.